SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Dash (DASH) is digital cash designed to offer financial freedom to everyone. Payments are instant, easy and secure, with near-zero fees. Built to support real life use cases, Dash is the leading decentralized payment solution. Users can purchase goods at thousands of merchants and trade it at major exchanges and brokers around the globe. Since its creation in 2014, Dash has demonstrated leadership in innovation and pioneered groundbreaking features such as: -Two-tier network with incentivized nodes and decentralized project governance (Masternodes) -Instantly settled payments (InstantSend) -Instantly immutable blockchain (ChainLocks) -Optional privacy (PrivateSend)

Dash

Dash is trending as traders speculate on its potential to follow the recent performance of other privacy coins like Zcash, with many pointing to its limited supply and the possibility of a short squeeze. Community discussion remains polarized, with some bullish investors anticipating a significant breakout, while others express frustration over stagnant price action and compare the asset to other alternatives.

Onyx is an infrastructure for a multi-asset, scalable, and cryptographically secure ledger. Onyx functions as a blockchain-based technology that enhances financial ecosystems by enabling a more efficient and interconnected economy, with a mission to develop cryptographic ledgers that optimize security, scalability, and usability. XCN is native to the Onyx XCN Ledger Blockchain as well as the Onyx Goliath Blockchain. XCN is also used as an ERC-20 token for Staking and Governance.

Onyxcoin

Onyxcoin is seeing increased volatility and trading volume following its listing on the Upbit exchange. While some in the community view this development as a positive catalyst for future adoption and institutional interest, others are dismissing the price action as a recurring pump-and-dump scheme.

Hedera is a decentralized public network where developers can build secure, fair applications with near real-time consensus. The platform is owned and governed by a council of global innovators including Avery Dennison, Boeing, Deutsche Telekom, DLA Piper, FIS (WorldPay), Google, IBM, LG Electronics, Magalu, Nomura, Swirlds, Tata Communications, University College London (UCL), Wipro, and Zain Group.   The Hedera Consensus Service (HCS) acts as a trust layer for any application or permissioned network and allows for the creation of an immutable and verifiable log of messages. Application messages are submitted to the Hedera network for consensus, given a trusted timestamp, and fairly ordered. Use HCS to track assets across a supply chain, create auditable logs of events in an advertising platform, or even use it as a decentralized ordering service.

Hedera Hashgraph

The community is currently divided, with some traders accumulating HBAR during the recent price decline while others express frustration over the asset's underperformance compared to other sectors. Despite the ongoing price volatility, discussion remains focused on long-term utility, enterprise adoption within the Hedera council, and speculation surrounding the future impact of legislative developments on crypto assets.

Amarin Corp. Plc is a pharmaceutical company, which focuses on the commercialization and development of therapeutics for cardiovascular health. It focuses on the development and commercialization of Vascepa capsules. The company was founded by Geoffrey William Guy on March 1, 1989 and is headquartered in Dublin, Ireland.

Amarin Corp - ADR

Amarin is trending as traders analyze the potential outcomes of the Supreme Court remand regarding the Hikma litigation, alongside ongoing speculation about future pipeline catalysts like a new formulation and a potential buyout.

Zcash is a privacy-focused cryptocurrency that uses trustless zero-knowledge proofs to enable fully encrypted transactions while maintaining blockchain transparency and security. It was the first cryptocurrency to implement zero-knowledge encryption for private peer-to-peer payments, addressing the fundamental privacy gap in traditional cryptocurrencies that expose transaction details publicly.   With a fixed supply of 21 million ZEC and a halving schedule similar to Bitcoin, Zcash allows users to prove transactions are valid without revealing sensitive information like wallet balances, transaction amounts, or participant identities, making it suitable for everyday payments, long-term savings, and cross-border money transfers where financial confidentiality matters.  The protocol operates on its own blockchain currently using Proof-of-Work consensus, though it's evolving toward Proof-of-Stake through the planned "Crosslink" upgrade to enhance security, scalability, and energy efficiency. Zcash employs trustless zero-knowledge proofs (Halo) within its Orchard shielded pool to verify transactions without revealing sender, receiver, or amount information.   Users can choose between transparent public transactions and shielded private transactions through Unified Addresses, which work with both types. The network is faster and cheaper than Bitcoin, with new blocks mined every 75 seconds and transaction fees typically just a fraction of a cent. Privacy adoption has surged in 2025, with over 30% of total ZEC supply now held in fully shielded pools.  Zcash was created by a group of scientists in 2013 who initially proposed Zerocoin as a privacy extension to Bitcoin before building a standalone protocol. The ecosystem operates with a self-funded development model where block rewards support independent teams through the Zcash Community Grants Committee and a new Coinholder-Controlled Fund.

Zcash

Zcash is experiencing a significant rally, driven by strong community speculation about institutional accumulation, the anticipation of a potential ETF, and its role as a leading privacy-focused alternative to Bitcoin. Traders are actively debating whether the momentum will sustain the push toward higher psychological price levels or lead to an inevitable correction.

Algorand is a scalable, secure, and decentralized digital currency and smart contract platform. Its protocol uses a variation of Proof-of-Stake (PoS) called Pure PoS (PPoS) to secure the network and reach consensus on block production. Developers can build decentralized applications (dApps) using familiar programming languages, including Python, which Algorand supports natively. Its infrastructure enables various use cases, including payment systems, digital identity solutions, supply-chain tracking, and financial services. The protocol's architecture allows for tokenization of assets and the development of smart contracts, while its technical specifications support both retail users seeking basic transaction capabilities and enterprises requiring more, complex, blockchain solutions.

Algorand

Algorand is trending as market participants debate its long-term potential, with bulls highlighting the network's post-quantum cryptography roadmap and recent institutional liquidity partnerships. Conversely, critics frequently dismiss the project as a "scam" or "dead," pointing to historical price declines and ongoing concerns regarding token dilution.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

The community conversation is fragmented, with traders debating whether Internet Computer is an undervalued infrastructure play with significant potential in decentralized AI or a long-term underperformer suffering from poor tokenomics and failed marketing. While some investors remain highly bullish based on long-term technological developments and ecosystem growth, others express deep frustration with price action and historical leadership decisions.

Dogecoin is an open-source digital currency based on the "Doge" meme that functions as a peer-to-peer medium for fast payments and digital tipping. Unlike projects backed by corporate entities, its value is driven by a global community, and the project is managed by a decentralized group of volunteers and the non-profit Dogecoin Foundation rather than a formal company.  Originally created in 2013 by software engineers Billy Markus and Jackson Palmer as a market parody, the project held no public sale or venture capital rounds. The network operates as a fork of LuckyCoin, which itself was a fork of Litecoin, using a proof of work consensus mechanism. It employs the Scrypt algorithm to ensure the mining process remains fast and efficient, with new blocks processed every 60 seconds. A unique technical feature is its use of merged mining, allowing miners to secure Dogecoin simultaneously with other Scrypt-based networks like Litecoin.  To keep transaction fees low and the network running indefinitely, Dogecoin features an uncapped supply where new coins are added forever. In a major regulatory milestone in March 2026, a joint SEC and CFTC framework officially classified Dogecoin as a digital commodity, placing it in the same asset category as gold or oil.

Dogecoin

Dogecoin is experiencing a mix of accumulation and profit-taking as traders debate its potential to break through resistance levels, with many pinning hopes on a broader crypto bull run. While some express frustration over recent price stagnation and volatility, others maintain long-term optimism, often citing the asset's historical role in meme culture and speculative price targets.

Subsquid Network is an innovative decentralized data lake and query engine designed to offer developers performant and permissionless access to data, aiming to build a neutral and open internet rooted in Web3 principles. Secured by ZK proofs, the Subsquid network boasts a modular architecture that enables exceptional scalability and developer convenience optimized for blockchain indexing, dApp development, and analytics.  Subsquid is a response to unscalable and rigid monolithic indexing frameworks that had previously gained popularity and market traction among Web3 developers. Today, these frameworks are struggling to adapt in a rapidly evolving blockchain environment. Additionally, the network serves as a highly efficient and decentralized alternative to centralized infrastructure firms, including large RPC and API providers.

Attention is centered on the reported Google Cloud validation of Rezolve's distributed database technology and its connection to Subsquid, which traders view as major infrastructure validation. While many are bullish on the project's enterprise-adoption narrative, others remain skeptical, questioning whether the partnership primarily benefits Rezolve rather than the SQD token directly.

Robinhood GLD is a tokenized representation of SPDR Gold Shares (GLD) common stock, issued on Robinhood Chain, Robinhood's own blockchain built to bring tokenized real-world assets on-chain. Each token is designed to track the price of the underlying GLD share, giving holders on-chain price exposure to SPDR Gold Shares's stock. The token is freely transferable and composable across the Robinhood Chain ecosystem. It's part of Robinhood's broader initiative to expand access to tokenized U.S. equities via blockchain technology, alongside a wider lineup of tokenized stock tokens launching on the same network.

GoldCoin

The community discussion is fragmented, with the primary themes being technical analysis of potential support and resistance levels for GoldCoin and comparisons against other assets like gold and bitcoin. Traders also frequently debate the merits of trading strangles and the impact of macroeconomic data, such as jobs reports and interest rate expectations, on the asset's price action.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Rs 325–4,200/month: Dr Reddy’s, Sun Pharma, Glenmark kick off generic semaglutide price war

… Reddy’s Laboratories, Sun Pharma , Glenmark Pharmaceuticals , Alkem Laboratories, Zydus Lifesciences … , and Natco Pharma . Eris Lifesciences, which has a … first Indian pharma company to receive approval from the Drugs Controller General …

India’s Eris launches $14 monthly generic Ozempic shot, among cheapest globally

India’s Eris Lifesciences on Friday launched one of the most affordable versions of Ozempic so far, with the lowest dosage of generic semaglutide starting at 1,290 rupees ($13.8) per month. Launch under the brand Sundae in India for diabetes, with lowest dose of a Sundae vial, at 2 mg. Natco Pharma, Eris’ partner for the semaglutide launch, priced its lowest 2 mg dose at 1,290 rupees a month. Eris also plans to launch a pen device version of Sundae in April, in three dosages. The lowest 2 mg dose will cost 4,000 rupees per month and the highest 8 mg dose 4,500 rupees per month. Eris is among dozens of Indian drugmakers that are launching generic semaglutide as Danish drugmaker Novo Nordisk’s semaglutide patent is set to expire on March 20. Novo Nordisk patent expiry opens door to cheaper weight-loss drugs in India Larger peer Dr Reddy’s is expected to launch on Saturday. Indian generic drugmakers, known globally for producing low-cost medicines, are expected to price their generics at discounts of at least 50% to 60%.

Eris Lifesciences, Natco Pharma ink pact on Semaglutide

Eris Lifesciences has forged a strategic partnership with Natco Pharma for commercialisation of semaglutide in India.

Eris Lifesciences Ltd announces Strategic Partnership with Natco Pharma Ltd for Semaglutide Launch in India

… strategic partnership with Natco Pharma Limited for the commercialisation … Natco Pharma has received approval from the Central Drugs Standard … Bulls Keywords ErisLifesciences INE406M01024 Pharmaceuticals Partnership NatcoPharma Semaglutide IndiaLaunch

Natco Pharma, Eris Lifesciences shares jump up to 6% on partnership for Semaglutide launch in India

Shares of Natco Pharma and Eris Lifesciences climbed on Tuesday after announcing a partnership to commercialise Semaglutide in India. Natco rose over 6% to its highest level since January 8, while Eris gained nearly 4%, marking its third straight session of gains.

Eris Lifesciences partners Natco to commercialise semaglutide

Eris Lifesciences has partnered with Natco Pharma to introduce semaglutide in the Indian market a cutting-edge therapy for Type 2 diabetes and obesity management. By combining Eris’s strong commercial network with Natco’s proven production capabilities, the alliance expands Eris’s diabetes care portfolio with a high-impact, next-generation treatment.

Eris Lifesciences/Natco Pharma partner on semaglutide for India

Natco Pharma has received regulatory approval in India, paving the way for a launch in March 2026

Brief India: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY and more

In this briefing: Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update 1. Swiggy (3QFY26 Results Review): FD Beats Expectation, QC Burn Likely Peaked. Maintain BUY Overall B2C GOV grew 49% YoY (8.6% QoQ) to reach INR 181.2bn (in-line) Consolidated adj EBITDA losses stood at INR7.1bn (in-line) Food delivery (FD) GOV grew 20.5% YoY to INR 89.6bn (HSIE: INR 88bn) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below. 2. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Brief India: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY and more

In this briefing: Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY ICICI Prudential AMC (ICICIAMC IN): Partial Global Index Inclusion with Low Float What Does Silver's Volatility Mean for Markets? Auto Sector Update: India EU FTA Update Union Budget 2026- What We like and What We Don't 1. Eris Lifesciences: Steady Growth Visibility; Valuation in Comfort Zone. Upgrade to BUY We upgrade Eris Lifesciences (Eris) to BUY (from ADD) with a TP of INR 1,730, based on a 28x Q3FY28E EPS (vs 31x Q2FY28E; implies EV/ EBITDA of 16x and PE of 24x for ex-amortization EPS), as we believe since our downgrade to ADD in Jul-25, the stock price has corrected (down 25% in the last six months), which factors in the growth concern in key therapies Now, the valuation has turned attractive (trading at 36/ 26/ 21x on FY25/26/27E PE vs its 5-year average of ~25x) and is providing comfort We expect Eris to focus on the execution phase after its aggressive investments (multiple M&As over FY23–25 and invested INR 38–40bn) for the next few years with focus on anti-diabetic (insulins), obesity (GLP-1) categories, and new FDC launches (~20+ in FY27) Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only.

Medical Community joins forces on Republic day to address the Silent Crisis of Hypertension at One India Conclave

• Unveils India’s First Hypertension Anthem • National Doctors’ Movement Gains Momentum to Bridge the Diagnosis-to-Control Gap Across India MUMBAI, India, Jan. 27, 2026 /PRNewswire/ — Marking the 77th Republic Day with a call for national health unity, Eris Lifesciences hosted the One India Conclave to address the growing crisis of hypertension in the country. […]

Eris Lifesciences Ltd. engages in the provision of pharmaceutical products. Its brands include Eritel, Glimsave, Renerve, Tendia, Olmin, Rabonik, Tayo, Cyblex, Remylin, Zomelis, Crevast, Atorsave, Ginkocer and Metital. The firm markets and distributes pharmaceutical drugs, such as tablets, syrups and injections. The company was founded by Amit Indubhushan Bakshi on January 25, 2007 and is headquartered in Ahmedabad, India.

Current Price	1,319.00
Prev Close	1,300.00
Open	1,301.00
Dividend Yield	0.00%
50-Day Moving Average	1,386.22
Beta	N/A
Avg. Volume	80,511.52
PE Ratio	28.11

52-Week High	1,745.00
52-Week Low	1,200.00
Market Capitalization	183.9B
EPS (Annual)	45.33
Price to Book	4.69
Revenue Per Employee	10.17M

Feed

News

Sentiment

Fundamentals

Info

ERIS.NSE Fundamentals